| Literature DB >> 32387682 |
Yan Ma1, Qing-Nan Xu1, Feng-Li Wang1, Xiao-Man Ma1, Xiao-Yan Wang1, Xiao-Guo Zhang2, Zhong-Fa Zhang3.
Abstract
Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) is continuously and rapidly circulating at present. Asymptomatic patients have been proven to be contagious and thus pose a significant infection control challenge. Here we describe the characteristics of asymptomatic patients with SARS-CoV-2 infection in Jinan, Shandong province, China. A total of 47 patients with confirmed COVID-19 were recruited. Among them, 11 patients were categorized as asymptomatic cases. We found that the asymptomatic patients in Jinan were relatively young and were mainly clustered cases. The laboratory indicators and lung lesion on chest CT were mild. No special factors were found accounting for the presence or absence of symptoms. The presence of asymptomatic patients increased the difficulty of screening. It is necessary to strengthen the identification of such patients in the future.Entities:
Keywords: Asymptomatic; COVID-19; Characteristics; SARS-CoV-2
Mesh:
Year: 2020 PMID: 32387682 PMCID: PMC7204664 DOI: 10.1016/j.micinf.2020.04.011
Source DB: PubMed Journal: Microbes Infect ISSN: 1286-4579 Impact factor: 2.700
Baseline characteristics of patients infected with SARS-CoV-2.
| Item | All cases | Asymptomatic | Symptomatic | P-value |
|---|---|---|---|---|
| No. (%) | 47 | 11(23.4) | 36(76.6) | – |
| Age, years(median, range) | 34(1–72) | 23(1–60) | 35.5(3–72) | 0.179 |
| Age group (n, %) | 0.069 | |||
| <18 | 10(21.3) | 5(45.5) | 5(13.9) | |
| ≥18 | 37(78.7) | 6(54.5) | 31(86.1) | |
| Gender (N, %) | 0.568 | |||
| Male | 20(42.6) | 6(54.5) | 14(38.9) | |
| Female | 27(57.4) | 5(45.5) | 22(61.1) | |
| Comorbidities | 11(23.4) | 2(18.2) | 9(25.0) | 0.952 |
| Exposure history | 0.683 | |||
| Resident of Wuhan | 9(19.1) | 3(27.3) | 6(16.7) | |
| Recent travel to Wuhan | 4(8.5) | 0(0.0) | 4(11.1) | |
| Recent travel to other | ||||
| epidemic areas | 7(14.9) | 1(9.1) | 6(16.7) | |
| Close contact with | ||||
| confirmed patients | 27(57.4) | 7(63.6) | 20(55.6) | |
| Cluster cases(N,%) | 35(74.4) | 9(81.8) | 26(72.2) | 0.807 |
| Family | 28(59.6) | 8(72.7) | 20(55.6) | |
| Other | 7(14.9) | 1 (9.1) | 6(16.7)) |
Clinical characteristics of patients infected with SARS-CoV-2.
| Item | All cases | Asymptomatic | Symptomatic | P-value |
|---|---|---|---|---|
| No. (%) | 47 | 11(23.4) | 36(76.6) | – |
| Diagnostic classification(N, %) | 0.077 | |||
| Mild case | 10(21.3) | 5(45.5) | 5(13.9) | |
| Common case | 36(76.6) | 6(54.5) | 30(83.3) | |
| Severe case | 1(2.1) | 0(0.0) | 1(2.8) | |
| Time from admission to | 0.182 | |||
| (days, median, range) | 13.5(3–39) | 10(3–34) | 16(5–39) | |
| Time of hospital stay | 0.004 | |||
| (days, median, range) | 22(10–44) | 14(10–30) | 22.5(12–44) | |
| Outcome(N, %) | 0.051 | |||
| Discharge | 45(95.7) | 9(81.8) | 36(100) | |
| Hospitalization | 2(4.3) | 2(18.2) | 0(0.0) |
Symptoms of patients infected with SARS-CoV-2.
| Items | N | Percentage, % |
|---|---|---|
| No. of patients | 36 | 100 |
| Symptoms | ||
| Fever | 28 | 77.8 |
| Dry cough | 17 | 47.2 |
| Expectoration | 4 | 11.1 |
| Fatigue | 4 | 11.1 |
| Sore throat | 4 | 11.1 |
| Myalgia | 4 | 11.1 |
| Headache | 2 | 5.6 |
| Coryza | 1 | 2.8 |
| Nausea and vomiting | 0 | 0.0 |
| Diarrhea | 0 | 0.0 |
Laboratory and radiological findings of patients infected with SARS-CoV-2.
| Items | All cases(n) | Asymptomatic (n, %) | Symptomatic (n, %) | P-value |
|---|---|---|---|---|
| No. of patients | 47 | 11(23.4) | 36(76.6) | – |
| White blood cell count ( × 109/L, normal range 4–10) | 47 | 1.000 | ||
| Decreased | 3(27.3) | 11(30.6) | ||
| Neutrophil count ( × 109/L, normal range 2–7) | 47 | 0.166 | ||
| Decreased | 1(9.1) | 9(25.0) | ||
| Increased | 1(9.1) | 0(0.0) | ||
| Lymphocyte count ( × 109/L, normal range 0.8–4) | 47 | 0.011 | ||
| Decreased | 0(0.0) | 4(11.1) | ||
| Increased | 4(36.4) | 1(2.8) | ||
| Platelet count ( × 109/L, normal range 100–300) | 47 | 0.151 | ||
| Decreased | 1(9.1) | 1(2.8) | ||
| Increased | 2(18.2) | 2(5.6) | ||
| Fibrinogen (g/L, normal range 2–4) | 43 | 0.122 | ||
| Decreased | 2(22.2) | 1(2.9) | ||
| Increased | 1(11.1) | 11(32.4) | ||
| D-dimmer (μg/ml, normal range 0–0.5) | 43 | 1.000 | ||
| Increased | 1(11.1) | 4(11.8) | ||
| C-reactive protein (mg/L, normal range 0.068–8.2) | 47 | 0.137 | ||
| Increased | 1(9.1) | 14(38.9) | ||
| Erythrocyte sedimentation rate (mm/H, normal range 0–15) | 47 | 0.722 | ||
| Increased | 3(27.3) | 14(38.9) | ||
| Lactate dehydrogenase (U/L, normal range 109–245) | 46 | 0.285 | ||
| Increased | 5(45.5) | 8(22.9) | ||
| Creatine kinase-MB (U/L, normal range 7–25) | 46 | 0.020 | ||
| Increased | 6(54.5) | 5(14.3) | ||
| Abnormalities on CT | 37 | 7(63.6) | 30(83.3) | 0.659 |
| Bilateral distribution of patchy shadows or ground glass opacity | 4(36.4) | 21(58.3) | ||
| Unilateral distribution of patchy shadows or ground glass opacity | 3(27.3) | 9(25.0) |
Fig. 1Representative lung images of an asymptomatic patient in which lesions developed in multiple lobes, most of which were subpleural ground-glass opacity co-existed with consolidation.
Fig. 2Dynamic changes of the chest CT of an asymptomatic patient obtained on February 5(A), February 8(B), February 14(C) and February 19(D).